SenzaGen new Chief Scientific officer Hernik Appelgren will give a presentation on 21st century testing for skin sensitisation and updates on application of the GARD platform at The 53rd European Congress of the European Societies of Toxicology, EUROTOX, on the 12th of Sept. SenzaGen is also Exhibiting at the congress and presenting two posters
The meeting promises scientific sessions houndreds of abstract presentations, exhibitors meetings, continuing education courses, awards presentations, receptions, and an exhibition area for exhibitors offering you the latest information on services and technology
Tuesday 12 Sep 10-11 AM | Memories, Hotel Sheraton
21st Century Sensitisation testing: Can one test be stand alone? Regulatory challenges and GARD applications update.
Presented by: Henrik Appelgren, Chief Scientific Officer and regulatory expert at SenzaGen
Allergy is a growing health problem in humans. The data requirements for the assessment of sensitisation in chemical legislations have been based on animal assays, which until now have served as the golden standard. However, in vitro assays have been developed which need to be combined in order to address all key events for sensitisation to fulfil the demands in e. g., Reach. However, The Genomic Allergen Rapid Detection Skin (GARDskin) assay addresses all the key regulatory questions regarding sensitisation, including potency – How? This session we will give an update on the validation status and the different applications of GARD.
ID 668 | Session 2 | Board no P-04-02-07 | Monday, Sept 11 from 15:00
Transferability of the GARDskin assay to two independent laboratories.
ID 438 | Session 4 | Board number P-09-02-31 | Tuesday, Sept 12 from 15:00
The GARD platform for potency assessment of skin sensitizing chemicals